Teva Pharmaceutical Industries Limited (TEVA) : The consensus price target for Teva Pharmaceutical Industries Limited (TEVA) is $72.59 for the short term with a standard deviation of $10.59. The most optimist securities analyst among the 15 who monitor the stock believes that the stock can reach $100, however, the pessimist price target for the company is $57.
Teva Pharmaceutical Industries Limited (TEVA) has an average broker rating of 1.68, which is interpreted as a Buy, as rated by 17 equity analysts. Nonetheless, 10 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 2 other analysts advise a Buy. Nevertheless, the majority of 5 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Also, BTIG Research maintains its rating on Teva Pharmaceutical Industries Limited (NYSE:TEVA). The global brokerage major maintains a current price target of $75 per share. Analysts at the BTIG Research have a current rating of Buy on the shares. The rating by the firm was issued on August 24, 2016.
Teva Pharmaceutical Industries Limited (NYSE:TEVA): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $50.18 and $50.15 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $51.21. The buying momentum continued till the end and the stock did not give up its gains. It closed at $50.90, notching a gain of 1.01% for the day. The total traded volume was 7,272,777 . The stock had closed at $50.39 on the previous day.
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.